Abstract 4538: BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity
Abstract The family of cyclin-dependent kinase (CDK) proteins consists of multiple cell cycle regulating CDK members as well as members involved in the regulation of gene transcription like CDK9/PTEFb (positive transcription elongation factor b). Inhibition of PTEFb and its direct downstream target...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 74; no. 19_Supplement; p. 4538 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.10.2014
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
The family of cyclin-dependent kinase (CDK) proteins consists of multiple cell cycle regulating CDK members as well as members involved in the regulation of gene transcription like CDK9/PTEFb (positive transcription elongation factor b). Inhibition of PTEFb and its direct downstream target RNA polymerase II is thought to cause rapid depletion of short-lived mRNA transcripts of important survival proteins like c-myc and Mcl-1 and thereby to induce growth delay and apoptosis in addicted tumor cells.
In contrast to pan-CDK inhibitiors which are currently evaluated in Phase I and II clinical trials, PTEFb selective inhibitors have not been explored for clinical utility.
BAY 1112054 is a potent and highly selective PTEFb-kinase inhibitor with low nanomolar activity against PTEFb/CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. Furthermore, BAY 1112054 shows a favourable selectivity against non-CDK kinases in vitro. The compound exhibits broad anti-proliferative activity against a panel of tumor cell lines with sub-micromolar IC-50 values.
In line with the proposed mode of action, a concentration-dependent inhibition of the phosphorylation of the RNA polymerase II was observed in A549 tumor cells. This inhibition was accompanied by a reduction of intracellular Mcl-1 protein levels. Furthermore, BAY 1112054 increased DNA fragmentation in synchronized HeLa cells upon compound treatment for 24 hours.
BAY 1112054 showed convincing in vivo efficacy at tolerated doses in two xenograft models in mice. Once daily oral treatment led to complete tumor stasis in established MOLM-13 AML xenografts. Pharmacokinetic analysis revealed that unbound plasma levels were 8 to 12 hours above the cellular IC50 in this model. In vivo efficacy and tolerability of the once daily po schedule of BAY 1112054 was confirmed in NCI-H82 SCLC xenografts. Xenografted tumors of this model showed lower levels of RNA polymerase II phosphorylation and Mcl-1 upon treatment with BAY 1112054.
In conclusion, our data provides in vitro and in vivo proof of concept for BAY 1112054, a potent and highly selective inhibitor of PTEFb/CDK9 with first-in-class potential, and warrant further clinical evaluation of PTEFb selective inhibitors for the treatment of cancers addicted to the transcription of short-lived anti-apoptotic survival proteins.
Citation Format: Arne Scholz, Ulrich Lücking, Gerhard Siemeister, Philip Lienau, Knut Eis, Antje Wengner, Kirstin Petersen, Ulf Bömer, Peter Nussbaumer, Axel Choidas, Gerd Rühter, Jan Eickhoff, Carsten Schultz-Fademrecht, Bert Klebl, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Michael Brands, Karl Ziegelbauer. BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4538. doi:10.1158/1538-7445.AM2014-4538 |
---|---|
AbstractList | Abstract
The family of cyclin-dependent kinase (CDK) proteins consists of multiple cell cycle regulating CDK members as well as members involved in the regulation of gene transcription like CDK9/PTEFb (positive transcription elongation factor b). Inhibition of PTEFb and its direct downstream target RNA polymerase II is thought to cause rapid depletion of short-lived mRNA transcripts of important survival proteins like c-myc and Mcl-1 and thereby to induce growth delay and apoptosis in addicted tumor cells.
In contrast to pan-CDK inhibitiors which are currently evaluated in Phase I and II clinical trials, PTEFb selective inhibitors have not been explored for clinical utility.
BAY 1112054 is a potent and highly selective PTEFb-kinase inhibitor with low nanomolar activity against PTEFb/CDK9 and an at least 50-fold selectivity against other CDKs in enzymatic assays. Furthermore, BAY 1112054 shows a favourable selectivity against non-CDK kinases in vitro. The compound exhibits broad anti-proliferative activity against a panel of tumor cell lines with sub-micromolar IC-50 values.
In line with the proposed mode of action, a concentration-dependent inhibition of the phosphorylation of the RNA polymerase II was observed in A549 tumor cells. This inhibition was accompanied by a reduction of intracellular Mcl-1 protein levels. Furthermore, BAY 1112054 increased DNA fragmentation in synchronized HeLa cells upon compound treatment for 24 hours.
BAY 1112054 showed convincing in vivo efficacy at tolerated doses in two xenograft models in mice. Once daily oral treatment led to complete tumor stasis in established MOLM-13 AML xenografts. Pharmacokinetic analysis revealed that unbound plasma levels were 8 to 12 hours above the cellular IC50 in this model. In vivo efficacy and tolerability of the once daily po schedule of BAY 1112054 was confirmed in NCI-H82 SCLC xenografts. Xenografted tumors of this model showed lower levels of RNA polymerase II phosphorylation and Mcl-1 upon treatment with BAY 1112054.
In conclusion, our data provides in vitro and in vivo proof of concept for BAY 1112054, a potent and highly selective inhibitor of PTEFb/CDK9 with first-in-class potential, and warrant further clinical evaluation of PTEFb selective inhibitors for the treatment of cancers addicted to the transcription of short-lived anti-apoptotic survival proteins.
Citation Format: Arne Scholz, Ulrich Lücking, Gerhard Siemeister, Philip Lienau, Knut Eis, Antje Wengner, Kirstin Petersen, Ulf Bömer, Peter Nussbaumer, Axel Choidas, Gerd Rühter, Jan Eickhoff, Carsten Schultz-Fademrecht, Bert Klebl, Stuart Ince, Franz von Nussbaum, Dominik Mumberg, Michael Brands, Karl Ziegelbauer. BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4538. doi:10.1158/1538-7445.AM2014-4538 |
Author | Klebl, Bert Ince, Stuart Siemeister, Gerhard Lienau, Philip Lücking, Ulrich Nussbaumer, Peter Wengner, Antje Nussbaum, Franz von Eis, Knut Rühter, Gerd Ziegelbauer, Karl Petersen, Kirstin Eickhoff, Jan Choidas, Axel Scholz, Arne Brands, Michael Schultz-Fademrecht, Carsten Mumberg, Dominik Bömer, Ulf |
Author_xml | – sequence: 1 givenname: Arne surname: Scholz fullname: Scholz, Arne – sequence: 2 givenname: Ulrich surname: Lücking fullname: Lücking, Ulrich – sequence: 3 givenname: Gerhard surname: Siemeister fullname: Siemeister, Gerhard – sequence: 4 givenname: Philip surname: Lienau fullname: Lienau, Philip – sequence: 5 givenname: Knut surname: Eis fullname: Eis, Knut – sequence: 6 givenname: Antje surname: Wengner fullname: Wengner, Antje – sequence: 7 givenname: Kirstin surname: Petersen fullname: Petersen, Kirstin – sequence: 8 givenname: Ulf surname: Bömer fullname: Bömer, Ulf – sequence: 9 givenname: Peter surname: Nussbaumer fullname: Nussbaumer, Peter – sequence: 10 givenname: Axel surname: Choidas fullname: Choidas, Axel – sequence: 11 givenname: Gerd surname: Rühter fullname: Rühter, Gerd – sequence: 12 givenname: Jan surname: Eickhoff fullname: Eickhoff, Jan – sequence: 13 givenname: Carsten surname: Schultz-Fademrecht fullname: Schultz-Fademrecht, Carsten – sequence: 14 givenname: Bert surname: Klebl fullname: Klebl, Bert – sequence: 15 givenname: Stuart surname: Ince fullname: Ince, Stuart – sequence: 16 givenname: Franz von surname: Nussbaum fullname: Nussbaum, Franz von – sequence: 17 givenname: Dominik surname: Mumberg fullname: Mumberg, Dominik – sequence: 18 givenname: Michael surname: Brands fullname: Brands, Michael – sequence: 19 givenname: Karl surname: Ziegelbauer fullname: Ziegelbauer, Karl |
BookMark | eNo9kEFOwzAURC1UJNrCEZB8gKb1T-zEYRdKC4giWHTDynIcpzFK7So2RT0CtyZREavRzP8zizdBI-usRugWyByA8QWwhEcZpWxevMYEaET74AKN__MRGhNCeMRoFl-hifefvWVA2Bj9FKUPnVQBD6U7fF98YACICaMzLHFjdk17wl63WgVz1DN8cEHbgKWtsOtk2x_lUZpWlq3GxjamNMF12NX4fbtal4vlw0s-w75x3x4rZ4_GKmN3fT2YKHzt-1c5DJtwukaXtWy9vvnTKdquV9vlU7R5e3xeFptI5ZxHKY1VkteQAtGJTHVWS2A0rUpCcgqUVwqqlKpKqqyumYpjRqFiRLM85UBknEwRO8-qznnf6VocOrOX3UkAEQNOMWATAzZxxikGMskvxaposw |
CitedBy_id | crossref_primary_10_1530_ERC_16_0466 |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1158/1538-7445.AM2014-4538 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 4538 |
ExternalDocumentID | 10_1158_1538_7445_AM2014_4538 |
GroupedDBID | --- -ET 18M 29B 2WC 34G 39C 476 53G 5GY 5RE 5VS 6J9 AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P PQQKQ RCR RHF RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ |
ID | FETCH-LOGICAL-c988-642c39f1610e3a6e7fa1546db0094148dc1d64cdac7ff5c22541d50e596810a23 |
ISSN | 0008-5472 |
IngestDate | Thu Sep 26 17:14:59 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 19_Supplement |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c988-642c39f1610e3a6e7fa1546db0094148dc1d64cdac7ff5c22541d50e596810a23 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1158_1538_7445_AM2014_4538 |
PublicationCentury | 2000 |
PublicationDate | 2014-10-01 |
PublicationDateYYYYMMDD | 2014-10-01 |
PublicationDate_xml | – month: 10 year: 2014 text: 2014-10-01 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationYear | 2014 |
SSID | ssj0005105 |
Score | 2.1770937 |
Snippet | Abstract
The family of cyclin-dependent kinase (CDK) proteins consists of multiple cell cycle regulating CDK members as well as members involved in the... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 4538 |
Title | Abstract 4538: BAY 1112054, a highly selective, potent and orally available inhibitor of PTEFb/CDK9, shows convincing anti-tumor activity |
Volume | 74 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NjtMwELbKIiEuiF_xLx-4pcmmSZw03LJllxVLEYiutJwix3HUiGy7alMQvAGvyxMwY8dxBCvEconaRJ6knS9jz_ibGUJeCMEmnBexWzBwV7EilzstfOkyiRdSnweqTef8XXx8Gr05Y2ej0c8Ba2nXFp74fmleyf9oFc6BXjFL9gqa7YXCCfgM-oUjaBiO_6TjrMBAhWidCAwK-vYH2ScHzEoAKyRFy3SwGnHzzdmqbjdg2PDsxbo1xHJMz4fL_AuvG5VDVa-WdQEvudo7eL84PCqwgO6rkxQHbpfrr1vFU8cAvUpubGu33Z0jEVPoNhTDxe4MEbVxunpCS7VhrJkfyjI1jTeIQ2A50EZFs7ON3ep_ixv5BzPxuWu9ctqA3e4j2B9reS5r01vktdyYGgFqKBgtvrNBo2F8YxL1TDlrs6cui3SDH09aM51EuhClseO624_Ba5qrtqiWP6QNNOpjMNmbr39OJAyTI_r7eNlcPZsdPizc_duE2tMclYPFpjmKyVFMrsXkKOYauR4kKUMa6skHW-GedbRb86u7rDMQs3_p0wzWU4OF0eI2udV5NDTT8LxDRnJ1l9yYd5yNe-SHQSlFQS8pYJR2GB1TTjVCaY_QMdX4pIBPqvFJe3zSHp90XVGFz31E55gqbFKLTWqxSQ0275PF0eFidux2DUBckcKrDq6xCNMKfBJfhjyWScVhwR-XBdJhwY0vxaSMI1FykVQVE2BVoknJfMlSLLLHg_AB2VutV_IhoYkvgtKf8ioJ0whLHhVhDJ5HFTIeJ2UwfUQ88y_mF7rMS_5X7T2-6oAn5KZF91Oy12528hmsZ9viuQLAL9HSk2k |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abstract+4538%3A+BAY+1112054%2C+a+highly+selective%2C+potent+and+orally+available+inhibitor+of+PTEFb%2FCDK9%2C+shows+convincing+anti-tumor+activity&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Scholz%2C+Arne&rft.au=L%C3%BCcking%2C+Ulrich&rft.au=Siemeister%2C+Gerhard&rft.au=Lienau%2C+Philip&rft.date=2014-10-01&rft.issn=0008-5472&rft.eissn=1538-7445&rft.volume=74&rft.issue=19_Supplement&rft.spage=4538&rft.epage=4538&rft_id=info:doi/10.1158%2F1538-7445.AM2014-4538&rft.externalDBID=n%2Fa&rft.externalDocID=10_1158_1538_7445_AM2014_4538 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |